Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E)
The purpose of this study is to access the efficacy and safety of GX-188E according the protocol in patients with Cervical Intraepithelial Neoplasia 2, 2/3 or 3 (CIN3)
Cervical Intraepithelial Neoplasia
BIOLOGICAL: GX-188E|BIOLOGICAL: Placebo
Number of participants with histopathological regression of cervical lesions to CIN1 or less, The number of participants with cervical lesions regress to CIN1 or less at the 36 week visit, 36 weeks
Number of participants with Clearance of HPV 16 or 18 in combination with histopathological regression of cervical lesions to CIN1 or less, The number of participants with clearance of HPV 16 or 18 in combination with histopathological regression of cervical lesions to CIN1 or less at the 36 week visit, 36 weeks
Not provided